Pfiz­er plans to study a third shot for its Covid-19 vac­cine in the youngest kids, push­ing back its time­line far­ther

Amer­i­can chil­dren un­der the age of five may not be vac­ci­nat­ed un­til mid-2022, as Pfiz­er said Fri­day that it’s go­ing to now test a third dose of its Covid-19 vac­cine in the tri­al.

The de­ci­sion comes as Pfiz­er an­nounced non-in­fe­ri­or­i­ty was not met for chil­dren be­tween the ages of two and five when com­pared to old­er teenagers in the cur­rent tri­al.

Pfiz­er pre­vi­ous­ly said it might ap­ply for an EUA in this youngest pop­u­la­tion by the end of De­cem­ber or ear­ly next year, but now says that if the three-dose study proves suc­cess­ful, Pfiz­er and BioN­Tech ex­pect to sub­mit da­ta to reg­u­la­tors to sup­port an EUA “in the first half of 2022.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.